Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
EditorialEditor’s Page

Theranostics: The Future is Now!

Kathy S. Thomas
Journal of Nuclear Medicine Technology September 2022, 50 (3) 185;
Kathy S. Thomas
Editor, JNMT
MHA, CNMT, PET, FSNMMI-TS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Overall, in the past 50+ years, the diagnostic and therapeutic capabilities of nuclear medicine and molecular imaging have significantly advanced thanks to the constant improvement in imaging technology and continuous addition of new diagnostic and therapeutic radiopharmaceuticals. Looking back, we have seen numerous changes. From the early days of planar imaging and limited therapeutic procedures, to the explosive excitement of cardiac imaging in the early 1980s enhanced with SPECT, to the advent of PET radiopharmaceuticals and technology, followed quickly by hybrid technology (SPECT/CT, PET/CT, and PET/MR), and the many therapeutics along the way to treat thyroid disease, blood disorders, inflammatory joint disease, malignant effusions, bone metastasis, non-Hodgkin’s lymphoma, and liver metastasis—yes, we’ve come a long way!

But today, excitement in nuclear medicine and molecular imaging lies in the new frontier of theranostics —a term comprising therapeutics and diagnostics. Theranostics is used to describe the ability to combine a radioactive drug tagged to a receptor found on a tumor cell membrane to image the tumor cell and a therapeutic radionuclide (e.g., 177Lu or 90Y) tagged to the same receptor to target and kill the tumor cell. To highlight the advancements of Theranostics, this issue of JNMT has been dedicated to innovations in this field.

Four continuing articles set the stage for understanding the application of theranostics in a clinical setting. The first article introduces the concept of basic biochemistry and molecular biology as it relates to today’s radiopharmaceuticals (1). Next, Soulek describes the logistical considerations for implementing a 177Lu-DOTATATE program to treat neuroendocrine tumors (2). 177Lu-PSMA is an effective treatment for prostate cancer. Parent et al. highlight the treatment protocol’s benefits and emphasize the need for close internal collaboration for streamlined patient care (3). The final continuing education article focuses on treating osteoblastic osseous metastatic disease for castration-resistant prostate cancer without visceral metastases and the technical issues to consider when implementing this therapeutic protocol (4). Three Practical Protocol Tips (177Lu-DOTATATE, 177Lu-PSMA, and 223Ra-dichloride) follow each of their respective continuing education articles to provide a detailed protocol that can be clipped and incorporated into your procedure manual.

In an Invited Perspective, the Technologist Section’s Advocacy Committee explores required training for the nuclear medicine technologist to successfully participate in current and future theranostic protocols and notes that “nuclear medicine technologists are well‐positioned to take an active lead in theranostics growth and advancement” (5).

Radioiodine is the first theranostic radionuclide used for imaging and therapy; however, the challenges associated with radioiodine therapy are patient-specific in terms of dosimetry and clinical limitations. Kumar et al. (6) summarize the considerations of radioiodine therapy for differentiated thyroid cancer with the clinical limitation of end-stage renal disease, and Oliveira et al. (7) describe the importance of residence time and dosimetry before radioiodine therapy.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Kathy S. Thomas, MHA, CNMT, PET, FSNMMI-TS

When reading time is available, check out the additional topics associated with theranostics in radionuclide therapy, quality and practice management, imaging, radiation safety, and teaching case studies included in this issue.

As always, JNMT continues to look for new topics, clinical research, continuing educational articles, protocols, tips, and pointers. If you have ideas or suggestions or are considering writing but need some help getting started, please contact me at ksthomas0412{at}msn.com. Help is available!! If writing isn’t your thing, but you’re willing to share your expertise by becoming a reviewer for JNMT, please contact me!

REFERENCES

  1. 1.↵
    1. Glasgow KW,
    2. Dillard M,
    3. Hertenstein E,
    4. George Justin A,
    5. Brady R
    A. Going nuclear with amino acids and proteins: basic biochemistry and molecular biology primer for the technologist. J Nucl Med Technol. 2022;50:186–194.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Soulek DK,
    2. Martin ME,
    3. Mastascusa NJ,
    4. Graves SA
    . Practical considerations for implementation of 177Lu-DOTATATE neuroendocrine tumor treatment programs. J Nucl Med Technol. 2022;50:195–202.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Parent EE,
    2. Savir-Baruch B,
    3. Gayed IW,
    4. et al
    . 177Lu-PSMA therapy. J Nucl Med Technol. 2022;50:205–212.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Grady E
    . Nuts and bolts of 223Ra-dichloride therapy. J Nucl Med Technol. 2022;50:215–221.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Beyder DD,
    2. Rickley CL,
    3. Peters TL,
    4. Iman JL,
    5. Arenas CM
    . The nuclear medicine technologist’s role in theranostics: SNMMI-TS Advocacy’s vision. J Nucl Med Technol. 2022;50: 224–227.
    OpenUrlFREE Full Text
  6. 6.↵
    1. Kumar M,
    2. Subramanian K,
    3. Tanwar KS,
    4. et al
    . Radioiodine therapy in patient with differentiated thyroid cancer and end-stage renal disease on maintenance hemodialysis: case report with review of literature. J Nucl Med Technol. 2022;50:228–232.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Oliveira CV,
    2. Camozzato TSC,
    3. Dorow PF,
    4. Pasqueta J
    . Analysis of residence time, effective half-life, and internal dosimetry before radioiodine therapy. J Nucl Med Technol. 2022;50:233–239.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 50 (3)
Journal of Nuclear Medicine Technology
Vol. 50, Issue 3
September 1, 2022
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Theranostics: The Future is Now!
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Theranostics: The Future is Now!
Kathy S. Thomas
Journal of Nuclear Medicine Technology Sep 2022, 50 (3) 185;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Theranostics: The Future is Now!
Kathy S. Thomas
Journal of Nuclear Medicine Technology Sep 2022, 50 (3) 185;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Turning the Calendar Page to 2025
  • Mastering the Art of Clinical Education: Essential Resources for Clinical Instructors
  • It’s All About You!
Show more Editor’s Page

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire